Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints.
^Awan, Farrukh T.; Hillmen, Peter; Hellmann, Andrzej; Robak, Tadeusz; Hughes, Steven G.; Trone, Denise; Shannon, Megan; Flinn, Ian W.; Byrd, John C. (2014). "A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch". British Journal of Haematology. 167 (4): 466–77. doi:10.1111/bjh.13061. PMID25130401.